公开(公告)号：US20250000853A1

公开(公告)日：2025-01-02

申请号：US18826658

申请日：2024-09-06

Applicant: EISAI R&D MANAGEMENT CO., LTD. ,  Merck Sharp & Dohme LLC

Inventor： Andrew Evan Denker ,  Yu Kato ,  Kimiyo Tabata ,  Yusaku Hori

IPC: A61K31/47 ,  A61K39/00 ,  A61K39/395 ,  A61K45/06 ,  C07K16/28

Abstract: The present disclosure describes combination therapies comprising an antagonist of Programmed Death 1 receptor (PD-1) and a multi-RTK inhibitor, and the use of the combination therapies for the treatment of cancer. The multi-RTK inhibitor may be represented by Formula (I): wherein R1 is C1-6 alkyl or C3-8 cycloalkyl, R2 is a hydrogen atom or C1-6 alkoxy, and R3 is a hydrogen atom or a halogen atom. A tumor therapeutic agent is disclosed that combines a compound or pharmaceutically acceptable salt thereof represented by Formula I and an anti-PD-1 antibody.

公开(公告)号：US12083112B2

公开(公告)日：2024-09-10

申请号：US17502962

申请日：2021-10-15

Applicant: MERCK SHARP & DOHME LLC ,  EISAI R&D MANAGEMENT CO., LTD.

Inventor： Andrew Evan Denker ,  Yu Kato ,  Kimiyo Tabata ,  Yusaku Hori

IPC: A61K39/00 ,  A61K31/47 ,  A61K39/395 ,  A61K45/06 ,  C07K16/28

CPC classification number: A61K31/47 ,  A61K39/39558 ,  A61K45/06 ,  C07K16/2818 ,  C07K16/2827 ,  A61K2039/505 ,  A61K2300/00 ,  C07K2317/76 ,  A61K31/47 ,  A61K2300/00 ,  A61K39/39558 ,  A61K2300/00

Abstract: The present disclosure describes combination therapies comprising an antagonist of Programmed Death 1 receptor (PD-1) and a multi-RTK inhibitor, and the use of the combination therapies for the treatment of cancer. The multi-RTK inhibitor may be represented by Formula (I):




wherein R1 is C1-6 alkyl or C3-8 cycloalkyl, R2 is a hydrogen atom or C1-6 alkoxy, and R3 is a hydrogen atom or a halogen atom. A tumor therapeutic agent is disclosed that combines a compound or pharmaceutically acceptable salt thereof represented by Formula I and an anti-PD-1 antibody.

公开(公告)号：US20160089365A1

公开(公告)日：2016-03-31

申请号：US14862349

申请日：2015-09-23

Applicant: Eisai R&D Management Co., Ltd.

Inventor： Yu Kato ,  Sho Tachino ,  Takayuki Nakagawa ,  Kimiyo Tabata ,  Kiyoshi Okamoto ,  Yusaku Hori

IPC: A61K31/47

CPC classification number: A61K31/47

Abstract: An immunostimulatory compound is disclosed.

Abstract translation: 公开了免疫刺激化合物。

公开(公告)号：US11547705B2

公开(公告)日：2023-01-10

申请号：US15554577

申请日：2016-03-03

Applicant: MERCK SHARP & DOHME LLC ,  Eisai R&D Management Co., Ltd.

Inventor： Andrew Evan Denker ,  Yu Kato ,  Kimiyo Tabata ,  Yusaku Hori

IPC: A61K39/00 ,  A61K31/47 ,  A61K39/395 ,  A61K45/06 ,  C07K16/28

Abstract: The present disclosure describes combination therapies comprising an antagonist of Programmed Death 1 receptor (PD-1) and a multi-RTK inhibitor, and the use of the combination therapies for the treatment of cancer. The multi-RTK inhibitor may be represented by Formula (I): wherein R1 is C1-6 alkyl or C3-8 cycloalkyl, R2 is a hydrogen atom or C1-6 alkoxy, and R3 is a hydrogen atom or a halogen atom. A tumor therapeutic agent is disclosed that combines a compound or pharmaceutically acceptable salt thereof represented by Formula I and an anti-PD-1 antibody.

公开(公告)号：US11147806B2

公开(公告)日：2021-10-19

申请号：US15554577

申请日：2016-03-03

Applicant: MERCK SHARP & DOHME CORP. ,  Eisai R&D Management Co., Ltd.

Inventor： Andrew Evan Denker ,  Yu Kato ,  Kimiyo Tabata ,  Yusaku Hori

IPC: A61K39/00 ,  A61K31/47 ,  A61K39/395 ,  A61K45/06 ,  C07K16/28

Abstract: The present disclosure describes combination therapies comprising an antagonist of Programmed Death 1 receptor (PD-1) and a multi-RTK inhibitor, and the use of the combination therapies for the treatment of cancer. The multi-RTK inhibitor may be represented by Formula (I): wherein R1 is C1-6 alkyl or C3-8 cycloalkyl, R2 is a hydrogen atom or C1-6 alkoxy, and R3 is a hydrogen atom or a halogen atom. A tumor therapeutic agent is disclosed that combines a compound or pharmaceutically acceptable salt thereof represented by Formula I and an anti-PD-1 antibody.